Number of participants experiencing one or more episode requiring treatment with oral steroids · adults and children with chronic asthma
Combination fluticasone/salmeterol showed no clear difference in participants experiencing exacerbations requiring oral steroid… compared with budesonide/formoterol (moderate certainty).
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · adults and children with chronic asthma
Combination fluticasone/salmeterol showed no clear difference in participants experiencing exacerbations requiring admission to… compared with budesonide/formoterol (moderate certainty).
1 finding from 1 review
Asthma‐related serious adverse event · adults and children with chronic asthma
Combination fluticasone/salmeterol showed no clear difference in asthma‐related serious adverse event compared with budesonide/formoterol (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults and children with chronic asthma
1 finding from 1 review
Withdrawals due to adverse events · adults and children with chronic asthma
Combination fluticasone/salmeterol showed no clear difference in withdrawals (adverse events) compared with budesonide/formoterol (moderate certainty).
1 finding from 1 review
Functional status ‐ 6MWD (metres) · COPD and at least one other long‐term condition
1 finding from 1 review
Functional status ‐ 6MWD (metres) · COPD and at least one other long‐term condition
1 finding from 1 review
cAHI · adults with central sleep apnoea associated with heart failure
1 finding from 1 review
Cardiovascular mortality · adults with central sleep apnoea associated with heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with central sleep apnoea associated with heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of sleep · adults with central sleep apnoea associated with heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults with central sleep apnoea associated with heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
AHI · adults with central sleep apnoea associated with heart failure
1 finding from 1 review
All‐cause mortality · adults with central sleep apnoea associated with heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events at study endpoint · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse event—any—400/103 Duration of six months compared with placebo (low certainty).
2 findings from 1 review
OR 0.98 [0.75, 1.3]
890 participants
Low
OR 0.82 [0.62, 1.09]
894 participants
Low
Adverse events—serious—400/103 Duration of six months · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—400/103 Duration of six months compared with placebo (low certainty).
1 finding from 1 review
OR 1.09 [0.66, 1.79]
890 participants
Low
Adverse events—serious—200/103 Duration of six months · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—200/103 Duration of six months compared with placebo (low certainty).
1 finding from 1 review
OR 0.71 [0.41, 1.23]
894 participants
Low
Adverse events—any Duration of two years1 · COPD
Fluticasone/salmeterol (FPS) showed no clear difference in adverse events—any Duration of two years1 compared with placebo (low certainty).
1 finding from 1 review
OR 1.09 [0.95, 1.25]
5574 participants
Low
Adverse events—'serious' Duration of two years1 · COPD
Fluticasone/salmeterol (FPS) showed no clear difference in adverse events—'serious' Duration of two years1 compared with placebo (low certainty).
1 finding from 1 review
OR 1.08 [0.95, 1.23]
5531 participants
Low
Exercise capacity · people with pulmonary hypertension
1 finding from 1 review